Scarica l'app Stockscreener
154.38
0.08%
-0.13
Precedente Chiudi:
$154.51
Aprire:
$157.1
Volume 24 ore:
87,935
Relative Volume:
0.53
Capitalizzazione di mercato:
$6.17B
Reddito:
-
Utile/perdita netta:
$-77.61M
Rapporto P/E:
-67.18
EPS:
-2.2979
Flusso di cassa netto:
-
1 W Prestazione:
-2.74%
1M Prestazione:
-9.11%
6M Prestazione:
+37.32%
1 anno Prestazione:
+147.01%
Intervallo 1D:
$153.48
$158.95
Intervallo di 1 settimana:
$153.48
$160.24
Portata 52W:
$56.10
$200.00
Belite Bio Inc Adr Stock (BLTE) Company Profile
Nome
Belite Bio Inc Adr
Settore
Industria
Telefono
-
Indirizzo
-
Compare BLTE vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BLTE
Belite Bio Inc Adr
|
154.38 | 6.18B | 0 | -77.61M | 0 | -2.2979 |
VRTX
Vertex Pharmaceuticals Inc
|
424.36 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
702.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
794.70 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.11 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
297.49 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-26 | Iniziato | BofA Securities | Buy |
| 2026-01-06 | Iniziato | Morgan Stanley | Overweight |
| 2025-12-02 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-11-24 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-11-20 | Iniziato | Mizuho | Neutral |
| 2023-12-14 | Iniziato | Maxim Group | Buy |
| 2023-07-28 | Iniziato | Cantor Fitzgerald | Overweight |
| 2023-07-26 | Iniziato | SVB Securities | Outperform |
| 2022-08-01 | Iniziato | H.C. Wainwright | Buy |
| 2022-07-01 | Iniziato | The Benchmark Company | Buy |
Mostra tutto
Belite Bio Inc Adr Borsa (BLTE) Ultime notizie
Belite Bio chief scientific officer Nathan Mata sells $155,635 in shares - Investing.com
Belite Bio (NASDAQ: BLTE) CSO pre-planned sale of 1,000 ADS - Stock Titan
Belite Bio CSO Nathan Mata sells $155,777 in shares By Investing.com - Investing.com South Africa
Belite Bio (BLTE) CSO pre-planned sale of 1,000 ADS around $160 - Stock Titan
Belite Bio (BLTE) CSO sells 1,000 ADS in planned trades - Stock Titan
Belite Bio (BLTE) Initiates Rolling NDA Submission to FDA for Tinlarebant in STGD1 - Yahoo Finance
Belite Bio, Inc. Sponsored ADR (NASDAQ:BLTE) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
Dry Age-Related Macular Degeneration Pipeline Grows as 70+ Pharma Companies Advance Novel Therapies for Vision Loss, Finds DelveInsight | Belite Bio, Stealth BioTherapeutics, Ocugen, Alkeus - Barchart
Belite Bio (NASDAQ:BLTE) Insider Nathan Mata Sells 1,000 Shares - MarketBeat
(BLTE) Volatility Zones as Tactical Triggers - Stock Traders Daily
Belite Bio (NASDAQ: BLTE) CSO sells 1,000 ADS under 10b5-1 plan - Stock Titan
Belite bio CSO Nathan Mata sells $159,162 in shares - Investing.com
Belite bio CSO Nathan Mata sells $159,162 in shares By Investing.com - Investing.com India
Belite Bio (BLTE) CSO sells 1,000 ADS in planned open-market trades - Stock Titan
A Look At Belite Bio (BLTE) Valuation As Tinlarebant NDA Submission Progresses - Sahm
Belite Bio (NASDAQ:BLTE) Insider Sells $162,640.00 in Stock - MarketBeat
Belite Bio chief scientific officer Nathan Mata sells $162,641 in shares - Investing.com India
Belite Bio chief scientific officer Nathan Mata sells $162,641 in shares By Investing.com - Investing.com South Africa
Belite Bio (NASDAQ: BLTE) CSO sells 1,000 ADS under Rule 10b5-1 plan - Stock Titan
Belite Bio, Inc (BLTE) Presents at Deutsche Bank ADR Virtual Investor ConferenceSlideshow - Seeking Alpha
Belite Bio Shares Tinlarebant Phase III Stargardt Data, FDA Rolling Submission at DB Conference - MarketBeat
Transcript : Belite Bio, Inc Presents at Deutsche Bank ADR Virtual Investor Conference, Apr-28-2026 09 - marketscreener.com
Belite Bio (NASDAQ:BLTE) Insider Sells $159,560.00 in Stock - MarketBeat
Belite Bio chief scientific officer Nathan Mata sells $159,555 in stock - Investing.com India
Belite Bio (BLTE) CSO sells 1,000 ADS under Rule 10b5-1 plan - Stock Titan
Belite Bio Announces Oral Presentation at the Retinal Therapeutics Innovation Summit - The Manila Times
Belite Bio CSO Nathan Mata sells $166,283 in shares By Investing.com - Investing.com Australia
Belite Bio CSO Nathan Mata sells $166,283 in shares - Investing.com
Belite Bio (BLTE) CSO sells 1,000 ADS in Rule 10b5-1 trades - Stock Titan
Belite Bio CSO Nathan Mata sells $170,384 in shares By Investing.com - Investing.com South Africa
Belite Bio CSO Nathan Mata sells $170,384 in shares - Investing.com
BELITE BIO (BLTE) CEO gains 10,000 shares from vested RSUs - Stock Titan
[Form 4] BELITE BIO, INC Insider Trading Activity - Stock Titan
Belite Bio (BLTE) CFO RSUs vest into 10,000 ordinary shares - Stock Titan
Belite Bio to Participate in Four Upcoming Investor Conferences - markets.businessinsider.com
Four Belite Bio conference appearances are set from April 28 to May 26 - Stock Titan
Belite Bio chief scientific officer sells $166,000 in shares By Investing.com - Investing.com Canada
Belite Bio chief scientific officer sells $166,000 in shares - Investing.com
Belite Bio (NASDAQ: BLTE) CSO pre-planned sale of 1,000 ADS disclosed - Stock Titan
Buy Initiation on Tinlarebant Developer: First-Mover Stargardt Opportunity Drives DCF-Based $200 Target Amid Key Late-Stage Catalysts and Risks - TipRanks
Belite Bio to Present at the Deutsche Bank American Depositary Receipt Virtual Investor Conference on April 28th - marketscreener.com
Belite Bio (NASDAQ:BLTE) Receives Buy Rating from HC Wainwright - MarketBeat
Belite Bio begins rolling NDA submission for Stargardt treatment By Investing.com - Investing.com India
Belite Bio CSO Nathan Mata sells $163,594 in shares By Investing.com - Investing.com Canada
Belite Bio CSO Nathan Mata sells $163,594 in shares - Investing.com
Belite Bio begins rolling NDA submission for Stargardt treatment - Investing.com
Belite Bio Starts FDA Rolling NDA for Tinlarebant in Stargardt Disease - TipRanks
Belite Bio Inc Adr Azioni (BLTE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.14%
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):